IBA and Wallonie Entreprendre International secure 30% stake in mi2-factory to support improved efficiency of silicon carbide-powered devices
21 Janvier 2025 - 7:00AM
UK Regulatory
IBA and Wallonie Entreprendre International secure 30%
stake in mi2-factory to support improved efficiency of silicon
carbide-powered devices
Louvain-La-Neuve, Belgium, 21 January
2025 - IBA (Ion Beam Applications S.A., EURONEXT), the
world leader in particle accelerator technology, and Wallonie
Entreprendre International (WE International), the international
branch of the Walloon public investment company, today announce a
joint strategic investment of EUR 5 million each in mi2-factory, a
start-up and spin-off from the University of Applied Sciences Jena,
Germany. This investment secures a 15% stake for IBA and a 15%
stake for WE International.
mi2-factory specializes in nitrogen implantation
in silicon carbide (SiC), an important process to improve the
efficiency of SiC power semiconductor chips. Those chips are
essential components in modern power electronic systems serving in
a range of sectors, including electric mobility, energy generation
from wind and solar, renewable energy grids, among others. The
company focuses on high-energy implantation to simplify processes,
reduce cost, and enhance yield and quality of SiC chips and
wafers.
In line with its strong commitment to
innovation, IBA is proud to support mi2-factory in advancing its
lab-proven process towards industrial-grade solution. IBA’s
advanced compact particle accelerator technologies are ideally
suited to meet mi2’s ambitions of enabling SiC devices that combine
the best attributes of quality, cost, and production
capacity.
The development of mi2-factory is further
supported by a grant from the Important Project of Common European
Interest for Microelectronics and Communication Technologies (IPCEI
ME/CT) and equity investment from the company’s current
shareholders bringing its total additional resources to
approximately EUR 40 million. Beyond the economic prospects that
the development of this type of solution represents, the project
also marks a potential advancement in strengthening European
expertise in the strategic and rapidly growing field of power
electronics.
Prof. Dr. Michael Rüb, CEO &
Managing Director of mi2-factory, commented:
“mi2-factory was seeking not only strategic and technological
partners but also co-investors to strengthen our position in IPCEI
projects. Partnering with IBA, the world leader in particle
accelerator technologies, and Wallonie Entreprendre International,
a reputable institutional partner, reinforces our expertise and
know-how, positioning us as the best in class in high-energy
nitrogen implantation in silicon carbide as we look to advance
towards an industrial grade solution.”
Henri de Romrée, Deputy Chief Executive
Officer of IBA, added: “Investing in promising
companies like mi2-factory is part of our entrepreneurial DNA and
could lead to potential new applications for our accelerators. We
look forward to collaborating with the talented mi2-factory team
and contributing to this project to help grow European
expertise in power electronics, which is an important and strategic
sector.”
Laurence Glautier, General Manager of WE
International, commented : " We are proud to make
this co-investment alongside IBA, a long-standing partner with a
proven track record of innovation and a strong impact on the
Walloon region. This investment in a European project, backed by
IPCEI, aligns perfectly with our mission to support
high-value-added initiatives that foster Walloon expertise in
cutting-edge sectors like semiconductor in power electronics. By
encouraging IBA's diversification into this strategic domain, we
not only reinforce technological advancements but also ensure
long-term economic growth and skilled employment opportunities in
Wallonia.”
***
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle
accelerator technology. The company is the leading supplier of
equipment and services in the field of proton therapy, considered
to be the most advanced form of radiation therapy available today.
IBA is also a leading player in the fields of industrial
sterilization, radiopharmaceuticals and dosimetry. The company,
based in Louvain-la-Neuve, Belgium, employs approximately 2,000
people worldwide. IBA is a certified B Corporation (B Corp) meeting
the highest standards of verified social and environmental
performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).-More
information can be found at: www.iba-worldwide.com
About Wallonie Entreprendre
International
WE International (Wallonie Entreprendre International S.A.) is the
international branch of the Walloon public investment company
Wallonie Entreprendre S.A. For more than 20 years, WE International
is dedicated to finance Walloon companies with projects abroad that
generate significant economic benefits for the Walloon region. More
information can be found at :
https://www.wallonie-entreprendre.be/en/expertises/international/
About mi2-factory
mi2-factory GmbH (“mi2-factory”) offers a novel process technology
for semiconductor production with its innovative EFIITRON wafer
processing equipment. Chip manufacturers use EFIITRON to reduce
chip costs, to increase reliability and to realize new component
and wafer architectures.
The customer benefits from previously unattainable precision and
flexibility. This enables a cost reduction of up to 50% for silicon
carbide (SiC) chips. EFIITRON is targeting the strategic market of
silicon carbide power electronics for e-mobility, renewable energy
applications, AI data centers, traction and industrial drives.
Well-known studies expect a market volume in 2027 of > $6
billion with a CAGR of 30-40%. mi2-factory is targeting to process
more than 30% of all SiC wafers with EFIITRON equipment in the long
term.
More information on mi2, at
https://mi2-factory.com/
More information on IPCEI ME/CT, at:
https://ipcei-me-ct.eu/
For further information, please
contact:
IBA
Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com
For media and investor
enquiries:
ICR Healthcare
Amber Fennell, Angela Gray, Lucy Featherstone
+44 (0) 20 3709
5700
IBA@consilium-comms.com
- 250121-IBA-MI-2_Factory-Investment-EN2
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025